Connect with us

Business

What is Neuroplasticity and How Does Cannabis Help with That and Other Brain Health Issues?

Published

on

Cannabis helps protect the brain from injury and long term issues.

What Is Neuroplasticity? Why You Should Care, And How Cannabis Contributes To It

Neuroplasticity is the medical term given to the brain’s ability to adapt and changed based on its environment and experience. The neural networks in the brain can change, organize themselves, and even grow new connections because of its malleability.

It is known that younger brains, such as those of children, are generally more malleable. Their brains are more sensitive to experience compared to those of older adults. Aging causes the brain to degenerate over time, due to the lack of brain cells, leading to disorders such as Alzheimer’s. However, science tells us that older adults are still capable of experiencing neuroplasticity especially with the help of cannabinoids. Our very own brain contains cannabinoid receptors too, so when we consume cannabinoids, studies show that it can help create new brain cells, forge new synapses, and ensure the viability of existing brain cells.

Certain negative experiences such as stress, trauma, and depression can weaken the synapses in the brain, resulting in impaired memory, learning, and overall plasticity. Meanwhile, physical conditions such as strokes, inflammation (due to diet or exposure to stress), traumatic brain injuries (TBI) and others can also impair the brain’s ability to heal itself and forge new connections.

Again, that’s where cannabis can help.

Here’s what the studies have to say:

Cannabinoids Reduce Plaque Proteins Which Leads to Alzheimer’s Disease

2016 study conducted by researchers at the La Jolla Salk Institute discovered that tetrahydrocannabinol (THC) as well as other cannabinoids can help get rid of amyloid beta, a protein considered as toxic because its accumulation can lead to Alzheimer’s disease especially in aging brains. The presence of amyloid beta is a hallmark feature of Alzheimer’s.

“Although other studies have offered evidence that cannabinoids might be neuroprotective against the symptoms of Alzheimer’s, we believe our study is the first to demonstrate that cannabinoids affect both inflammation and amyloid beta accumulation in nerve cells,” explains senior author David Schubert.

They also found that high levels of amyloid beta have been linked to cellular inflammation and higher risk for neuron death.

Cannabis Protects Neurons In Injured Brains and Traumatic Brain Injury (TBI)

2012 study involved researchers causing injuries on purpose, to the brains of rodent subject. They did this through repeated exposure to MDMA, carbon monoxide, and pentobarbital.

The rodents were administered with one low dose of THC, following the ratio of .002mg per kilogram of body weight. They found that just one low dose was protective against any damage to neurons, which are the cells in the nervous system responsible for transmitting signals and aiding us in memory, thinking, movement, and other cognitive functions.

2019 study that was published in the medical journal, Brain Injury, found that while cannabis use had no impact on the recovery time for those who suffered concussions, it was linked to a reduction in symptom burden especially during the 3rd and 4th weeks following injury.

Additionally, a July 2020 literature review stated that “the use of cannabinoids in TBI increases neurobehavioral function and working memory performance.” They explain that it does this through the “down-regulation of pro-inflammatory markers, edema formation and blood-brain barrier permeability, preventing neuronal cell loss and up-regulating the levels of adherence junction proteins.”

Cannabis Aids In Neurogenesis

Neurogenesis is the name given to the process of creating new brain cells. Neurogenesis plays an important role in improving synaptic plasticity, regulating our moods, and better memory.

There have been several studies proving how cannabis contributes to neurogenesis. In one study out of Italy, scientists discovered that cannabichromene (CBC), one of the lesser known cannabinoids in marijuana, can actually contribute to the growth of brain cells through neurogenesis.

In another study conducted by researchers from the University of Saskatchewan in Canada, they sought to understand how cannabinoids impact the brain. Mice were injected with a synthetic drug called HU210, which is 100 times more potent than THC. A chemical tracer was then used to monitor the growth of any new cells. They found that HU210 was effective in promoting the growth of new brain cells, similar to how antidepressants work. “Most ‘drugs of abuse’ suppress neurogenesis,” says Dr. Zhang, who participated in the study. “Only marijuana promotes neurogenesis.”

Other studies show that cannabidiol (CBD) is just as beneficial as THC for the brain, but both CBD and THC have neurogenic properties. “The pro-neurogenic effects of CBD might explain some of the positive therapeutic features of CBD-based compounds,” report German scientists back in 2010. In addition, CBD and THC have antidepressant properties, as well as other compounds in the cannabis plant, which help humans adapt to exposure to stress and injury.

Cannabis Aids In Healing of Mental Health Disorders

Many mental health disorders are affected by neuroplasticity. For one, post-traumatic stress disorder, which is characterized by recurrent nightmares, severe anxiety, and flashbacks. Trauma can change the actual structure of one’s brain, so there is a physical explanation to the changes in how the brain works.


Studies show that cannabis can help heal the brain and in doing so, help individuals heal from PTSD. A recent study revealed that CBD can boost blood flow to the brain, and positively affect memory processing. “There is evidence that CBD may help reduce symptoms of psychosis and anxiety. There is some evidence to suggest that CBD may improve memory function,” says the study’s lead author, Dr. Michael Bloomfield.

“Additionally, CBD changes how the brain processes emotional memories, which could help to explain its reputed therapeutic effects in PTSD and other psychiatric disorders,” he adds.

Conclusion

With all the valuable mechanisms that cannabis can help the human brain, it certainly is an excellent all-natural way to support our cognitive functions while also healing from emotional distress or brain injury. Making cannabis a part of your wellness regimen is a great way to give your brain the support it needs.

Source: https://cannabis.net/blog/medical/what-is-neuroplasticity-and-how-does-cannabis-help-with-that-and-other-brain-health-issues

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News